Drug

Fluticasone furoate

Approved · EMA

Emerging researchLate-stage development

Also known as Arnuity, Breo, Flonase, Flonase Sensimist+7 more

Arnuity, Breo, Flonase, Flonase Sensimist, Flovent, Fluticasone, Fluticasonum furoas, Furoate de fluticasone, Furoato de fluticasona, Trelegy, Veramyst.

RxNorm705022 ChEMBLCHEMBL1676UNIIJS86977WNV

Research papers

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma

Clinical trial2024-01-17Results posted · ClinicalTrials.gov

Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.

Clinical trial2024-01-01Primary completion · ClinicalTrials.gov

Medical vs Surgical Treatment Decision in Pediatric Obstructive Sleep Apnea Using Sleep Questionnaire

Clinical trial2023-05-31Primary completion · ClinicalTrials.gov

A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma

Clinical trial2020-10-28Results posted · ClinicalTrials.gov

A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol 100/25mcg Versus Fluticasone Furoate 100mcg on Asthma Control in Patients With Uncontrolled Asthma

Clinical trial2019-05-29Withdrawn · ClinicalTrials.gov

The Effect of Once-daily Fluticasone Furoate on Methacholine-induced Bronchoconstriction in Mild Asthmatics

Clinical trial2019-04-01Completed · ClinicalTrials.gov

A 6-month, Open Label, Randomised, Efficacy Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via the Dry Powder Inhaler ELLIPTA™ Compared With Usual ICS/LABA Maintenance Therapy Delivered by Dry Powder Inhaler in Subjects With Persistent Asthma

Clinical trial2019-01-14Results posted · ClinicalTrials.gov

A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Clinical trial2018-10-10Results posted · ClinicalTrials.gov

A Randomised, Placebo-controlled, Double-blind, Two Period Crossover Study to Characterise the Exhaled Nitric Oxide Time Profile as a Biomarker of Airway Inflammation in Adult Asthma Patients Following Repeat Administration of Inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.

Clinical trial2018-08-28Results posted · ClinicalTrials.gov

A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease

Clinical trial2018-08-06Results posted · ClinicalTrials.gov

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis.

Research2011-03-05The Journal of allergy and clinical immunology

Approval: Avamys (EMA)

Regulatory2008-01-11EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Fluticasone furoate

Aliases & brands

ArnuityBreoFlonaseFlonase SensimistFloventFluticasoneFluticasonum furoasFuroate de fluticasoneFuroato de fluticasonaTrelegyVeramyst

RxNorm CUI

705022

ChEMBL ID

CHEMBL1676

UNII

JS86977WNV

Regulatory jurisdictions

ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2008-01-11

Latest approval

2008-01-11

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2008-01-11Approval

Approval: Avamys (EMA)

Indication: Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.